Delivery Order SPE2DB22D3016-SPE2DB25FBHP4
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $16,071.75 to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes, with an ultimate completion date of August 5, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $36,928.09 delivery order to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes, with an ultimate completion date of July 28, 2025. This is a firm fixed-price, non-set-aside contract executed on July 26, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $19,310.96 to AmerisourceBergen Drug Corp for the supply of Prolia 60 mg/ml syringes. The contract was competitively awarded without set-aside designation and carries a firm fixed price structure with an ultimate completion date of September 9, 2025. AmerisourceBergen will perform the work from its corporate office in Conshohocken, Pennsylvania, serving as a critical pharmaceutical supplier within the federal medical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $15,697.68 to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes, with an ultimate completion date of September 4, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Prolia 60 mg/mL syringes, valued at $9,104.04 under firm fixed price terms. The award, issued on August 7, 2025, with completion targeted for August 8, 2025, represents a child delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $29,291.77 to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Prolia 60 mg/ml syringes. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract carries no set-aside designation, indicating open...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Prolia 60 mg/ml syringes with a ceiling value of $42,639.34. This firm fixed-price delivery order, which must be completed by August 11, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The award was competitively awarded with no...
- This delivery order, awarded August 5, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, provides for the supply of Prolia 60 mg/mL syringes valued at $14,236.24 with an ultimate completion date of August 6, 2025. The award utilizes firm fixed-price pricing with no set-aside designation, indicating competitive procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the...
- The Defense Logistics Agency awarded a delivery order valued at $7,591.46 to AmerisourceBergen Drug Corp for the supply of Prolia 60 mg/ml syringes. This firm fixed-price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by August 22, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $4,723.10 by the Defense Logistics Agency on August 5, 2025, for the supply of Prolia 60 mg/ml syringes. The contract utilizes firm fixed price terms and carries an ultimate completion date of August 6, 2025. This award is unset-aside and was competitively awarded through the federal procurement process. The delivery order will be fulfilled from the vendor's Corporate Office...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBHP4Delivery Order
The Defense Logistics Agency awarded a $35,094.09 delivery order to AmerisourceBergen Drug Corp for Prolia 60 mg/mL syringes on September 8, 2025, with an ultimate completion date of September 9, 2025. This firm fixed-price delivery order represents a competitively awarded non-set-aside contract executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The pharmaceutical product will be delivered to AmerisourceBergen's corporate headquarters location in Conshohocken, Pennsylvania. This award exemplifies AmerisourceBergen's role as a critical pharmaceutical distributor within the federal medical supply chain, particularly for Defense Health Agency and military healthcare requirements. As a major pharmaceutical distributor, AmerisourceBergen maintains an extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. The SPE2DX IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply medical commodities to support military healthcare programs worldwide, and the DLA Troop Support is planning to establish Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple regional awards, demonstrating the strategic importance of vendors like AmerisourceBergen to federal medical procurement operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $35.1k | 9/8/25 |